The application discloses a specific
T cell epitope peptide screened by a whole
proteome of S1, N and M proteins of a novel
coronavirus and application, relates to the technical field of biological
medicine, and its technical points are: the application provides a plurality of CD4+ T and CD8+
T cell epitope polypeptides of the novel
coronavirus, and the genes, recombinant proteins or complexes containing the
epitope polypeptides, sensitized
antigen presenting cells and specific
immune effector cells for the epitope polypeptides are used in the development of a novel
coronavirus vaccine and the treatment of diseases.The polypeptide provided by the application is screened from the
peripheral blood sample of a recovered person who breaks through infection of Omicron BA.5 after
inactivated vaccine booster
vaccination, and can safely and effectively induce CD4+ T and CD8+
T cell immune responses to the novel coronavirus
protein, and has important guiding significance for the development of a novel coronavirus vaccine.